Perspectives and limits of cancer treatment in an oldest old population

Beatrice Di Capua1 · Andrea Bellieni2 · Domenico Fusco2 · Maria Antonietta Gambacorta1 · Luca Tagliaferri1 · Emanuele Rocco Villani2 · Roberto Bernabei2 · Vincenzo Valentini1 · Giuseppe Ferdinando Colloca1

Received: 19 November 2020 / Accepted: 17 February 2021 / Published online: 11 March 2021
© The Author(s) 2021

Abstract

Background Population of oldest old will grow dramatically in the next future and cancer, physiologically related to aging, will be very prevalent among them. Lack of evidence is a huge problem to manage cancer in oldest old and will be more and more in the next years.

Aims Our purpose was to investigate the characteristics of a population of oldest old patients with cancer treated in the Radiation Oncology Unit of Fondazione Policlinico A. Gemelli IRCCS.

Methods We conducted a retrospective study. The primary outcome was to evaluate which characteristics of the population could influence the choice of oncological treatment (with radical or non-radical intent).

Results We identified a total of 348 patients: 140 were on follow-up; 177 were under treatment; 31 were considered not eligible for treatments. Patients under treatment had a high comorbidity index (mean Charlson Comorbidity Index 5.4), and a high prevalence of polypharmacy (mean number of drugs 5.6). More than half (53.1%) was treated with radical intent. Patients treated with radical intent were 1 year younger (87.1 years old vs 88.1 years old), more performant (ECOG 0.7 vs 1.3), and had less prevalence of metastatic neoplasia (6.4% vs 34.9%); comorbidities and drugs did not show differences in the two groups.

Conclusion Oldest old, usually not considered in international guidelines, are treated for oncological disease, often with radical intent. The treatment seems not to be tailored considering comorbidities but on performance status.

Keywords Oldest old · Geriatric oncology · Personalized medicine · Cancer · Elderly · Radiation oncology

Introduction

The scientific community is preparing to the so-called “Silver Tsunami”: in the next future, the population of elderly people will grow, and it will deeply change the world and the healthcare scenario. People born in the years of the economic boom, “baby boomers”, are estimated to be 73 million to date in United States [1]. These people are destined to enter and fill up in few years the group of oldest old. The term “oldest old” is used to refer to people aged 85 years or older. In United States this is the population group that is growing faster: it is expected by 2050 oldest old in United States they will triple in number.

Aging is characterized by high number of comorbidities and high prevalence of polypharmacy and disability. Moreover, cancer is deeply related to aging: by 2030 70% of all cancer diagnosis will be made in elderly. Aging is associated with fundamental changes in health status that makes elderly at high risk of being frail such as sense organs deficits, chronic disabling diseases [2], cognitive impairment and cancer, all conditions related to aging and frailty. Polypharmacotherapy is also very prevalent in older adults [3]; it relates to drugs interactions and drugs adverse events, especially in oldest old with cancer [4].
Despite the rising interest in oldest old, they are rarely enrolled in clinical trial, because of their complexity, and this determine serious lack of evidence and specific guidelines, especially those regarding cancer [5–7]. It’s very difficult, to date, to make evidence-based decision on treatment for oldest old with cancer and predict response to treatments [8]. In the report “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis” written in 2013 by the American Institute of Medicine, it is underlined the urgency of having evidence on elderly patient with cancer [8, 9]. Recently an important epidemiologic study made in United States on oncological patients aged 85 or older was published; the study showed that, to date, 8% of all new cancer diagnosis are made in the oldest old [10].

Oldest old are a great mystery for science: on one side they have more comorbidities and disabilities, on the other they seem to have some protective factors that reduce the risk of some diseases. In the next future, when baby boomers will join the group, we can imagine that this population will grow and change more and more. We must work now to be ready to these needs, especially in oncological field, since cancer will be a relevant issue for them. The aim of our study was to investigate the characteristics of a population of oldest old treated by the Radiation Oncology Unit in a University Hospital, and how these features affect the intent of the prescribed oncological treatment.

Materials and methods

We conducted a retrospective study to investigate the characteristics of a population of oldest old patients treated in the Radiation Oncology Unit (Gemelli ART—Advanced Radiation Oncology) of Fondazione Policlinico A. Gemelli IRCCS involving also the patient treated with Interventional Radiotherapy (brachytherapy) at Interventional Oncology Center of the same institution [11]. We analyzed medical records of patients aged 85 years or older, which have been evaluated by the Radiation Oncology Unit from June 2018 to May 2019.

We separated the outpatients on follow-up (group A) from the patients treated with radio-oncological treatment (radiotherapy and/or chemotherapy and/or hormone therapy and/or surgery) (group B) and the patients considered not eligible for treatments at the time of the evaluation (group C).

For all patients, we collected socio-demographic data and data regarding cancer. For patients belonging to group B, we also collected data regarding type of treatment, toxicities developed, comorbidities, and drugs. A subgroup of patients from group B, did not undergo the treatment prescribed for personal choice or performed it in another hospital; for them, we could not collect data regarding toxicities.

Primary outcome was to evaluate which characteristic of the population could influence the choice of the oncological treatment (treatment with radical vs not radical intent).

For radical intent, we mean a treatment whose target is to eradicate cancer. Treatment with not radical intent may be palliative if its target is to control a specific symptom (pain, bleeding etc.) or local tumor control when the purpose is to slow down or interrupt as long as possible cancer growth.

Statistical analysis

All data are presented as mean ± standard deviation (SD) or median and interquartile range (IQR) when referring to continuous variables and as frequency and related percentage when referring to categorical variables, unless otherwise specified. To detect differences between patients treated with radical intent and patients treated with not radical intent, continuous data were analyzed by Student’s t test or Mann–Whitney U test where appropriate. Categorical data were analyzed through Chi-square or Fisher exact test where appropriate. A p value < 0.05 was considered significant and reported as such. SPSS 20.0 (IBM Inc.) for Windows was used for all the analyses.

Results

We identified a total of 348 patients that have been evaluated by the Unit of Radiation Oncology from June 2018 to May 2019. Within this group 140 were outpatients on follow-up (group A); 177 patients received a radio-oncological treatment (radiotherapy and/or chemotherapy and/or hormone therapy and/or surgery) (group B); 31 patients were considered not eligible for treatments at the time of the evaluation (group C) (Fig. 1).

Patients of group B received all a radio-oncological treatment. Someone was treated with radiotherapy alone or radiotherapy with concomitant chemotherapy or hormone therapy. For radiotherapy treatment have been included both patients went under external beam radiotherapy or interventional radiotherapy (brachytherapy). Moreover, patients who did a radiotherapy treatment for prostate or breast cancer continued to be followed up during hormone therapy if prescribed. We also decided to collect data on patients undergoing surgical procedures in the same year.

Among patients in group B, 161 completed the treatment in our Hospital, while 16 patients were treated in a different Hospital or decided not to undergo the prescribed therapy. Those oldest old patients were 5.3% of all patients treated at our center between June 2018 and May 2019. We focused our analysis on group B.

Group B was homogenous for sex (50.8% male), and the mean age was 87.6 years old (minimum age 85 years...
old, maximum age 99 years old). The population had a high comorbidity index (mean Charlson Comorbidity Index 5.4, without considering cancer), and a high prevalence of polypharmacy (mean number of drugs 5.6). The mean value of ECOG (Eastern Cooperative Oncology Group) performance status was 1. 19.8% of patients were treated for a metastatic cancer (Table 1). Among the 177 patients, 129 (72.9%) were treated with radiotherapy alone, 60 (33.9%) were treated also with hormone therapy and 22 (12.4%) underwent chemotherapy too. 18 patients (10.2%) had a surgical procedure in the previous year, of whom 10 underwent breast surgery, 4 underwent pulmonary lobectomy, 3 underwent gastrointestinal surgery. Regarding the purpose of the oncological treatment, 94 patients (53.1%) were treated with radical intent, 35 patients (19.8%) for local tumor control, and 48 patients (27.1%) with palliative intent (Fig. 2). It is important to underline that patients undergoing palliative treatment were not necessarily terminal.

Breast cancer was the most prevalent cancer (18.6%), followed by prostate cancer (16.4%), skin cancer (13.6%), lung cancer (9.0%), colon rectal cancer (9.0%), kidney and urinary tract cancer (7.9%), gynecological cancer (6.8%) and head and neck cancer (6.2%) (Table 2).

In this group, only 27 patients (15.3%) had a formal oncogeriatric consultation; 74.1% of geriatric consultations were asked for comprehensive geriatric assessment and clinical

### Table 1 General characteristics of patients undergoing treatment

|                        | 177 patients (100%) |
|------------------------|---------------------|
| Male sex (n, %)        | 90 (50.8%)          |
| Age (years) (mean, SD) | 87.6                |
| CCI (mean, SD)         | 5.4                 |
| ECOG (mean, SD)        | 1.0                 |
| Number of drugs (mean, SD) | 5.6             |
| Metastatic disease (n, %) | 35 (19.8%)        |
| Radiotherapy (n, %)    | 129 (72.9%)         |
| Hormone therapy (n, %) | 60 (33.9%)          |
| Chemotherapy (n, %)    | 22 (12.4%)          |
| Surgery (n, %)         | 18 (10.2%)          |
| Radical intent (n, %)  | 94 (53.1%)          |
| Local tumor control intent (n, %) | 35 (19.8%) |
| Palliative intent (n, %) | 48 (27.1%)        |
| Geriatric Consultation (n, %) | 27 (15.3%) |

CCI: Charlson Comorbidity Index

### Table 2 Prevalence of tumor site in patients undergoing treatments

| Tumor Site                | Prevalence   |
|---------------------------|--------------|
| Breast                    | 33 (18.6%)   |
| Prostate                  | 29 (16.4%)   |
| Skin                      | 24 (13.6%)   |
| Lung                      | 16 (9.0%)    |
| Colon and rectum          | 16 (9.0%)    |
| Urologic                  | 14 (7.9%)    |
| Gynecologic               | 12 (6.8%)    |
| Head and neck             | 11 (6.2%)    |
| Liver and biliary tract   | 8 (4.5%)     |
| Soft tissue               | 7 (4.0%)     |
| Lymphoma                  | 3 (1.7%)     |
| Brain                     | 2 (1.1%)     |
| Eye                       | 1 (0.6%)     |
| Esophagus                 | 1 (0.6%)     |
evaluation before starting the treatment, 25.1% were asked for a clinical problem or an emerging symptom (Table 1).

An overall acute and/or subacute toxicity was detected in only 10.6% of patients (17 on 161 patient); in two cases the toxicity was relevant (grade 3, cutaneous toxicity). In the other cases, there were hematological, cutaneous, neurological or gastrointestinal toxicity of grade 1 or 2. Six patients interrupted the treatment for toxicity or for other clinical reasons; one of them restarted the treatment. One patient died during the treatment.

We divided patients who were undergoing oncological treatment in two groups and compared them: the first group (94 patients) includes patients who were treated with radical intent, the second group (83 patients) includes patients treated with not radical intent (local tumor control or palliative intent). These two groups were compared for general characteristics, type of treatment, treatment intent and tumor site (Table 3). The two groups were homogeneous for sex and number of drugs taken. Patients treated with radical intent were one year younger (mean age 87.13 years old vs 88.08 years old; \( p = 0.024 \); difference between the two groups means − 0.96; 95% CI − 1.76 to − 0.15, data not shown), showed better functional status (mean ECOG 0.7 vs 1.3; \( p < 0.001 \); difference between the two groups means − 0.6; 95% CI − 0.88 to − 0.31, data not shown) and had less prevalence of metastatic neoplasia (6.4% vs 34.9%; \( p < 0.001 \); absolute reduction of risk − 81.2%, 95% CI − 69.1 to − 89.3%) than those treated without radical intent. Radiotherapy was less frequently prescribed to patients treated with radical intent, being the estimated proportion for radical intent 53.2% (95% CI from 45.3% to 64.9%) while the estimated proportion for palliative intent where 92% (95% CI from 85.1% to 96.6%), with a \( p \) value < 0.001. Those data lead to an absolute reduction of radiotherapy use of − 37.4% (95% CI − 48.2 to − 25.1%) between patient treated with radical intent vs those treated with palliative intent. On the other hand, hormone therapy and surgery were more frequently prescribed for those treated with radical intent. Breast and prostate cancers were more prevalent in the group of patients treated with radical intent (breast cancer 29.8% vs 6.0%, \( p < 0.001 \); prostate cancer 23.4% vs 8.4%; \( p = 0.007 \)), while lung cancer was more prevalent in those treated with not radical intent (4.3% vs 14.45%; \( p = 0.033 \)).

Table 3 Comparison between patients treated with radical and not radical intent

|                              | Radical intent (n = 94) | Palliative intent/local tumor control (n = 83) | \( p \) value |
|------------------------------|------------------------|-----------------------------------------------|---------------|
| Male sex (n, %)              | 45.7% (43)             | 56.6% (47)                                    | 0.148         |
| Age (median, IQR)            | 87 (86–88)             | 87 (86–90)                                    | 0.181         |
| Age (mean, SD)               | 87.13 (2.05)           | 88.08 (3.29)                                  | 0.024         |
| Charlson comorbidity Index (mean, SD) | 5.22 (1.1655)       | 5.67 (1.5333)                                 | 0.055         |
| ECOG (mean, SD)              | 0.7 (0.5517)           | 1.3 (0.8786)                                  | <0.001        |
| Number of drugs (DS)         | 5.3 (2.9808)           | 5.9 (3.0374)                                  | 0.268         |
| Metastatic disease (n M1)    | 6.4% (6)               | 34.9% (29)                                    | <0.001        |
| Radiotherapy (n, %)          | 55.3% (52)             | 92.8% (77)                                    | <0.001        |
| Chemotherapy (n, %)          | 16.0% (15)             | 8.4% (7)                                      | 0.130         |
| Hormone therapy (n, %)       | 51.1% (48)             | 14.5% (12)                                    | <0.001        |
| Surgery (n, %)               | 18.1% (17)             | 1.2% (1)                                      | <0.001        |
| Interrupted treatment (n, %) | 5.0% (4)               | 1.5% (1)                                      | 0.32          |
| CGA (n, %)                   | 21.1% (19)             | 9.6% (8)                                      | 0.06          |
| Breast (n, %)                | 29.8% (28)             | 6.0% (5)                                      | <0.001        |
| Prostate (n, %)              | 23.4% (22)             | 8.4% (7)                                      | 0.007         |
| Lung (n, %)                  | 4.3% (4)               | 14.5% (12)                                    | 0.033         |
| Skin (n, %)                  | 11.7% (11)             | 15.7% (13)                                    | 0.442         |
| Urologic (n, %)              | 2.1% (2)               | 13.3% (11)                                    | 0.07          |
| Head and neck (n, %)         | 2.1% (2)               | 10.8% (9)                                     | 0.12          |
| Gynecologic (n, %)           | 9.6% (9)               | 3.6% (3)                                      | 0.21          |
| Esophagus and stomach (n, %) | 0% (0)                 | 1.2% (1)                                      | 0.87          |
| Colon and rectum (n, %)      | 6.4% (6)               | 12.0% (10)                                    | 0.26          |
| Liver and biliary tract (n, %)| 2.1% (2)              | 7.2% (6)                                      | 0.32          |
| Brain (n, %)                 | 1.1% (1)               | 1.2% (1)                                      | 0.95          |

\( p \)-value for distribution of the variable between frail and non-frail patients is in italic when significant at < 0.05 level
Discussion

The first important result of our study is that, despite the lack of specific indications in international guidelines, a high number of oldest old undergoes oncological treatments in our department. The second important result is that more than half of them received a treatment with radical intent.

In all our sample, the treatment more frequently proposed was, of course, radiotherapy, since our population belongs to this Unit. The high number of oldest old patients treated with radiotherapy confirms the evidence that this is an ideal therapy for older adults [12, 13]. The second more frequent treatment was hormone therapy, because of the large prevalence of breast and prostate cancer. In oldest old women, the prescription of hormone therapy as adjuvant therapy in patients who undergo surgery, should be well evaluated, according to functional status and life expectancy [14–16]. Although hormone therapy is considered a safe and well-tolerated therapy, the possible side effects must be evaluated and followed to avoid complications: hormonal blockade can have negative effects on cognitive, metabolic, and muscular systems [17–23]. Considering the importance of these syndromes on elderly people, it will become more and more urgent in the future to have strong evidence available to improve support therapy. The modern society will soon face to a new scenario, a world with a high number of oldest old patients that will probably be generally healthier than previous generations, but with a high prevalence of cancer disease.

We also observed, despite the age and the lack of specific indications on guidelines, that a considerable part of our population underwent chemotherapy and surgery. For what concerns chemotherapy, the population is rather heterogeneous, with a prevalence of colon rectal cancer and gynecological neoplasia; for surgery, the most prevalent tumors were breast cancer and gynecological cancer. We know that breast surgery, to date, is characterized by noninvasive techniques that can assure a radical target in early stages and can be safely offered to frailty patients.

Our population of treated patients was homogeneous for sex. We know indeed that women are more long-lived but they get old with more disabilities [24], so it is possible that they are considered less frequently for an oncological treatment. The mean age of our population was high, 87 years old, and the maximum age was 99 years old.

The characteristics of the population in treatment are accordan with literature: the population is characterized by a high comorbidity index (mean CCI 5.4 without considering the tumor) and high prevalence of polypharmacy (almost half of the patients took five drugs or more) [2]. These two characteristics are homogeneous between the group of patients treated with radical intent and patients treated without radical intent. These data suggest that neither the number of comorbidities, neither the number of drugs is considered in the choice, whereas performance status and disease stage are the fundamental elements taken into consideration by radiation oncologists to design the treatment plan. ECOG and disease stage are indeed the two parameters with which the oncologists have more confidence. Nevertheless, we should consider that comorbidities and polypharmacy increase the risk of side effect during oncological treatments and drugs interactions: gastro-enteric toxicity and dehydration in patients with cardiological and kidney disease, the use of corticosteroids in patients affected by type 2 diabetes mellitus, hypertension, osteoporosis or gastropathies, or the use in this population of antiplatelet agents, anticoagulants, hypoglycemic agents, diuretics, as well as vitamin D [25]. Liver and kidney failure can modify considerably chemotherapy metabolism with higher risk of toxicity and drugs interactions [26, 27].

It is important to underline that the high prevalence of polypharmaco-therapy is relevant for geriatric patients, because related to drugs interactions, inappropriate prescription, adverse events, and mortality. The prevalence of polypharmacy in our population is similar to general population of oldest old [28, 29].

We also investigated the prevalence of treatment-related toxicities that was quite low. Toxicities detected were low-grade toxicities but could be considered important for a frail patient. The low prevalence of toxicity can be explain in part by the fact that can be under reported in clinical records, but more likely by the fact that our center use the most recent technologies for radiotherapy, as Volumetric Modulated Arc Therapy or Stereotactic Body Radiation Therapy [30]. A very reliable and positive data are, indeed, that only five patients interrupted the treatment, which means that 97% of patients completed the treatment. In several studies investiga-ting the feasibility of chemotherapy in oldest old only 50% or less of patients could complete the chemotherapy planned [31, 32]. This difference suggests that radiotherapy is a treatment that fits perfectly to elderly with better predictable effects and higher possibility to complete the planned treatment.

As we mentioned earlier, comparing the group of patients treated with radical intent, and those treated without radical intent, we observed that the choice is made primarily on age, ECOG performance status, and metastatic disease. These data suggest that in oncology, also for the oldest old, functional status is considered one of the most important prognostic factors to take into account in therapeutic choices. Unfortunately, the only data we could collect on functional status was ECOG performance status that occurred in 102 records (57.6%
of records). The mean ECOG of treated patients was 1, that means a slight impairment in functional status; the difference between the two groups was almost of one point. Although performance status is the most frequent tool in oncology for measuring functional status, it is important to underline that it cannot be considered an effective surrogate of comprehensive geriatric assessment [33]. Anyway, most of the screening tools for elder patient with cancer also include ECOG [34].

Radiotherapy is more prevalent in the group of patients treated with palliative intent. Radiotherapy indeed is a very flexible technique that allows to adapt intensity and duration of the treatment according to the purpose of the treatment and it is well tolerated in old and frail patients. [35–37]

Hormone therapy is more prevalent in the group of patients treated with radical intent, because is used as adjuvant therapy in breast and prostate cancer to avoid relapses.

In our study, 27 on 177 patients had a geriatric evaluation (15.3%). About ¾ of these consultations were asked for comprehensive geriatric assessment and evaluation of the treatment proposed by the oncologist. About ¼ of the consultations were asked for the management of a clinical acute condition occurred during or after the treatment. An interesting data is that the consultation is asked more frequently when the patient is candidate to have a treatment with radical intent, although it was not statistically significant, probably due to the small number of patients involved. Although the number of geriatric consultations found in patients’ records is quite low, in our department, the presence of a geriatrician specialized in geriatric oncology and mainly involved in the Radiotherapy ward, allowed to create a special care pathway for frail patients that can undergo some treatments in a protected and supported condition.

We also observed 140 oldest old patients that were in follow-up. This high number of patients is the evidence that cancer is no more a terminal disease, but it can be treated with success also in elderly.

The main strength of our study is that we could evaluate in a high number of oldest old the main characteristics of their oncological treatments in a department of radiotherapy.

The main limitation of our study is that, since we collected data retrospectively, we could not record more data on functional status then ECOG performance status; moreover, some data on cancer stage and toxicity lack. Lastly it was not possible to estimate how many patients were not directed to an evaluation of treatment by the care provider, and so what is the real proportion of oldest old treated for cancer.

Conclusions

Our study shows how oldest old, usually not considered in international guidelines, are treated for oncological disease, often with radical intent. This result may be influenced by the fact that the university hospital from which the data were extrapolated represents a center of excellence with the constant presence of a geriatrician that is dedicated to oncological patients. The treatment seems not to be tailored considering comorbidities but on functional status, that is most of the time measured through performance status. Almost all patients completed the treatment without presenting serious toxicities.

We wish to have specific clinical trials tailored on oldest old, which will include comprehensive geriatric assessment and the evaluation of a multidisciplinary team for having robust data on tolerance and efficacy of new treatments on oldest old population.

Funding Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement. The author(s) received no financial support for the research, authorship, and/or publication of this article.

Compliance with ethical standards

Conflict of interest No author declares any conflict of interest.

Ethical approval Ethical approval for the study was obtained in all countries according to the local regulations.

Informed consent Patients were invited to take part in the study, and were free to decline participation. Consent was obtained with assurance of data confidentiality. Patients who did not give their consent were excluded from the study.

Materials availability Data supporting the findings of this study are available within the article and its supplementary material.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. United States Census Bureau (2019) 2020 Census will help policymakers prepare for the incoming wave of aging boomers.
2. Tsoi CS, Chow JY, Choi KS et al (2014) Medical characteristics of the oldest old: retrospective chart review of patients aged 85+ in an academic primary care centre. BMC Res Notes. https://doi.org/10.1186/1756-0500-7-340
3. Onder G, Bonassi S, Abbatecola AM et al (2014) High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian medicines agency (AIFA). J Gerontol Ser A Biol Sci Med Sci 69:430–437

4. Wang R, Chen L, Fan L et al (2015) Incidence and effects of polypharmacy on clinical outcome among patients aged 80+: a five-year follow-up study. PLoS ONE. https://doi.org/10.1371/journal.pone.0142123

5. Bernard MA, Clayton JA, Lauer MS (2018) Inclusion across the lifespan: NIH policy for clinical research. JAMA 320:1535–1536

6. Hurria A, Naylor M, Cohen HJ (2013) Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA 310:1795–1796

7. Tortorella L, Vizzelli G, Fusco D et al (2017) Ovarian cancer management in the oldest old: improving outcomes and tailoring treatments. Aging Dis 8:677–684

8. Freedman RA, Ruddy KJ (2019) Who are the patients in our clinical trials for cancer? J Clin Oncol 37:1519–1523

9. Levit LA, Balogh EP, Nass SJ et al (2014) Delivering high-quality cancer care: charting a new course for a system in crisis. Deliv high-quality cancer care charting a new course a syst cris. The National Academic Press (US), Washington (DC). https://doi.org/10.17226/18359

10. DeSantis CE, Miller KD, Dale W et al (2019) Cancer statistics for adults aged 85 years and older. 2019, CA Cancer J Clin 69:452–467. https://doi.org/10.3322/caac.21577

11. Kovács G, Tagliaferri L, Valentini V (2017) Is an interventional oncology center an advantage in the service of cancer patients or in the education? The Gemelli hospital and INTERACTS experience. J Contemp Brachyther 9:497–498

12. Pfeffer MR, Blumenfeld P (2017) The changing paradigm of radiotherapy in the elderly population. Cancer J 23:223–230

13. Colloca G, Tagliaferri L, Di Capua B, et al (2020) Management of The Elderly Cancer Patients Complexity: The Radiation Oncology Potential. Aging Dis 11:649–657. https://doi.org/10.14336/AD.2019.0616

14. Varghese F, Wong J (2018) Breast cancer in the elderly. Surg Clin North Am 98:819–833

15. Lee S-Y, Seo JH (2018) Current strategies of endocrine therapy in elderly patients with breast cancer. BioMed Res Int. https://doi.org/10.1155/2018/6078408

16. Pandolfi F, Franzia L, Mandolini C et al (2017) Immune modulation by vitamin d: special emphasis on its role in prevention and treatment of cancer. Clin Ther 39:884–893

17. Jaul E, Barron J (2018) Age-related diseases and clinical and public health implications for the 85 years old and over population. Front Public Heal 5:1–7

18. Harding C, Pompei F, Wilson R (2012) Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer 118:1371–1386

19. Bernard MA, Clayton JA, Lauer MS (2018) Inclusion across the lifespan: NIH policy for clinical research. JAMA 310:1795–1796

20. Pandolfi F, Franzia L, Mandolini C et al (2017) Immune modulation by vitamin d: special emphasis on its role in prevention and treatment of cancer. Clin Ther 39:884–893

21. Underwood EA, Rochon PA, Moineddin R et al (2018) Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res Treat 168:299–310

22. Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181:1998–2008

23. Mitsuzuka K, Arai Y (2018) Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol 25:45–53

24. Andersen-Ranberg K, Petersen I, Robine J-M, Christensen K (2005) Who are the oldest-old? In: Börsch-Supan A, Brugiavini A, Jürges H, Mackenbach J, Siegrist J, Weber G (eds) Health, ageing and retirement in Europe: first results from the survey of health, ageing and retirement in Europe. Mannheim Research Institute for the Economics of Aging, pp 35–40

25. Pandolfi F, Franzia L, Mandolini C et al (2017) Immune modulation by vitamin d: special emphasis on its role in prevention and treatment of cancer. Clin Ther 39:884–893

26. Nightingale G, Schwartz R, Kachur E et al (2019) Clinical pharmacology of oncology agents in older adults: a comprehensive review of how chronologic and functional age can influence treatment-related effects. J Geriatr Oncol 10:4–30

27. Underwood EA, Rochon PA, Moineddin R et al (2018) Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res Treat 168:299–310

28. Varghese F, Wong J (2018) Breast cancer in the elderly. Surg Clin North Am 98:819–833

29. Falandry C, Bonnemoy F, Freyer G, Gilson E (2014) Biology of cancer and aging: a complex association with cellular senescence. J Clin Oncol 32:2604–2610

30. Boldrini L, Colloca GF, Villani E, Chioloio G, Bellieni A, Manfrida S, Cellini F, Gambacorta MA, Valentini V (2020) Magnetic resonance-guided radiotherapy feasibility in elderly cancer patients: proposal of the MASTER scoring system. Tumori 107(1):26–31. https://doi.org/10.1177/0300891620920709

31. van Walree IC, van Breukelen ELG, Thilen N, van Rens MTM, van Huis-Tanja LH, Hamaker ME (2019) Chemotherapy in the oldest old: Choices and outcomes. Eur J Cancer Care (Engl) 28(4):e13049. https://doi.org/10.1111/ecc.13049

32. Ip E, Pokorny AMJ, Della-Fiorentina S et al (2017) Use of palliative chemotherapy in patients aged 80 years and over with incurable cancer: experience at three Sydney cancer centres. Intern Med J 47:75–81

33. Fusco D, Allocca E, Villani ER et al (2018) An update in breast cancer management for elderly patients. Transl Cancer Res 7:S319–S328

34. Amadio G, Marchetti C, Villani ER et al (2020) Tolerability of Bevacizumab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience. J Gynecol Oncol 31:e6

35. Colloca G, Tagliaferri L, Di Capua B, et al (2020) Management of The Elderly Cancer Patients Complexity: The Radiation Oncology Potential. Aging Dis 11:649–657. https://doi.org/10.14336/AD.2019.0616

36. Tagliaferri L, Lancellotta V, Colloca G et al (2019) The role of personalized interventional radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer. J Geriatr Oncol 10:514–517

37. Lancellotta V, Kovács G, Tagliaferri L et al (2019) The role of personalized interventional radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer. J Geriatr Oncol 10:514–517

38. Lancellotta V, Kovács G, Tagliaferri L et al (2018) Age is not a limiting factor in interventional radiotherapy (brachytherapy) for patients with localized cancer. Biomed Res Int 2018:1–10

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.